Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(13%)
Results Posted
100%(6 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
3
38%
Ph phase_2
4
50%
Ph phase_3
1
13%

Phase Distribution

3

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 24 (50.0%)
Phase 31 (12.5%)

Trials by Status

active_not_recruiting113%
terminated113%
completed675%

Recent Activity

1 active trials
Showing 5 of 8
terminatedphase_2

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

NCT03248492
completedphase_2

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

NCT04132960
active_not_recruitingphase_3

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319
completedphase_1

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

NCT03383692
completedphase_1

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

NCT03368196
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03248492Phase 2

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Terminated
NCT04132960Phase 2

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

Completed
NCT04622319Phase 3

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Active Not Recruiting
NCT03383692Phase 1

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Completed
NCT03368196Phase 1

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Completed
NCT03366428Phase 1

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Completed
NCT03329690Phase 2

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Completed
NCT03384940Phase 2

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8